B-17: Natural Amygdalin blocks cancer cells in vitro
It won’t please the skeptics much but a research study using natural B-17 (amygdalin) suggests that it may block cancer cells.
The following is taken from the abstract of the research covered in PLOSONE (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0105590)
Amygdalin, a natural compound, has been used by many cancer patients as an alternative approach to treat their illness. However, whether or not this substance truly exerts an anti-tumor effect has never been settled. An in vitro study was initiated to investigate the influence of amygdalin (1.25–10 mg/ml) on the growth of a panel of bladder cancer cell lines (UMUC-3, RT112 and TCCSUP). Tumor growth, proliferation, clonal growth and cell cycle progression were investigated. The cell cycle regulating proteins cdk1, cdk2, cdk4, cyclin A, cyclin B, cyclin D1, p19, p27 as well as the mammalian target of rapamycin (mTOR) related signals phosphoAkt, phosphoRaptor and phosphoRictor were examined.
Amygdalin dose-dependently reduced growth and proliferation in all three bladder cancer cell lines, reflected in a significant delay in cell cycle progression and G0/G1 arrest.
Molecular evaluation revealed diminished phosphoAkt, phosphoRictor and loss of Cdk and cyclin components. Since the most outstanding effects of amygdalin were observed on the cdk2-cyclin A axis, siRNA knock down studies were carried out, revealing a positive correlation between cdk2/cyclin A expression level and tumor growth.
Amygdalin, therefore, may block tumor growth by down-modulating cdk2 and cyclin A. In vivo investigation must follow to assess amygdalin´s practical value as an anti-tumor drug.
Ref: Makarević J, Rutz J, Juengel E, Kaulfuss S, Reiter M, et al. (2014) Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2.
Amygdalin can be found naturally, for example in Apricot Kernels.
For a full report on B-17, Laetrile, amygdalin and cancer CLICK HERE
CANCERactive - leading the way in Integrative Oncology.
It's the future of cancer treatment.